News

Abbott has announced the successful completion of the world’s first human leadless left bundle branch area pacing (LBBAP) procedures.

The company’s investigational Aveir conduction system pacing (CSP) leadless pacemaker was used as part of a feasibility study, marking the first-ever implantation of a leadless pacemaker in the left bundle branch area. Abbott reports that this innovation could replicate the heart’s natural rhythm, offering a promising new treatment option for patients with slow heart rates.

The procedures were conducted as part of the Leadless CSP feasibility study, which evaluates the safety and performance of the Aveir CSP system. Dr. Petr Neužil, head of cardiology at Na Homolce Hospital in Prague, Czech Republic, and principal investigator at the site, performed the procedures earlier this fall alongside Dr. Vivek Y. Reddy of Mount Sinai Hospital, the study’s principal investigator.

Conduction system pacing (CSP) involves implanting a traditional pacemaker deep within the heart wall to stimulate the left bundle branch area. This approach enables physiological pacing that closely mimics the heart’s natural electrical conduction.

By combining CSP techniques with leadless pacemaker technology, Abbott highlights the potential for unique benefits. Leadless systems eliminate the need for cardiac leads and pulse generators, reducing the risk of lead- and pocket-related complications.

Abbott’s Aveir CSP leadless system currently holds FDA breakthrough device designation.

“Bringing our proven leadless pacemaker technology to the left bundle branch area has great potential to be another transformative moment in cardiac care,” said Randel Woodgrift, SVP of Abbott’s cardiac rhythm management business. “By continuously innovating our approach to pacing, Abbott is revolutionizing care for millions of people living with slow or irregular heart rhythms.”


© Abbott Laboratories